Dimensional Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.6M	Buy	2,690,651 +1,461,799	+119%	+$11.4M	0.01%	1854
2025 Q4	$9.59M	Buy	+1,228,852	New	+$8.88M	﹤0.01%	2297
2014 Q3	–	Sell	-3,679	Closed	-$47K	–	3546
2014 Q2	$47K	Buy	3,679 +3,300	+871%	+$32.1K	﹤0.01%	3439
2014 Q1	$4K	Hold	379	–	–	﹤0.01%	3577
2013 Q4	$3K	Hold	379	–	–	﹤0.01%	3524
2013 Q3	$3K	Sell	379 -44,626	-99%	-$226K	﹤0.01%	3556
2013 Q2	$70K	Buy	+45,005	New	+$77.6K	﹤0.01%	3413

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Dimensional Fund Advisors's BCRX Position: Q1 2026 in Review

Dimensional Fund Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 119% in Q1 2026, buying an estimated $11.4M and bringing the position to 2,690,651 shares worth $25.6M. The position accounts for 0.01% of the portfolio, ranked #1854.

Dimensional Fund Advisors first reported a position in BCRX in Q2 2013 and has held it in 7 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Dimensional Fund Advisors held 2,690,651 shares of BioCryst Pharmaceuticals worth $25.6M as of Q1 2026.
Dimensional Fund Advisors bought 1,461,799 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $11.4M.
BioCryst Pharmaceuticals made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1854 holding.
Dimensional Fund Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.